Oral Iron For Treating Anemia Using Nanotechnology

描述（由申请人提供）：缺铁在慢性肾病（CKD）患者和许多其他人群中常见。目前口服铁制剂耐受性差。可注射的铁制剂难以施用、昂贵并且具有严重的并发症。 不良反应.因此，需要一种高度可吸收、耐受性良好的口服铁剂来补充红细胞生成刺激剂，以治疗与慢性肾病（CKD）相关的贫血。我们的铁替代剂将具有以下属性：1）口服递送，具有最小的不良事件，2）有效的肠道转运，进入血管系统，3）肝脏靶向，其中铁被释放到正常的铁储存中，以及4）成本有效的制造，为医疗经济提供节省。我们的第一阶段SBIR应用程序的目的是合成符合这一描述的原型产品。这将通过应用该公司的纳米技术专业知识来开发一种稳定的氧化铁胶体来实现，该胶体具有表面涂层，允许肠道运输，同时防止肠道内的细菌大量繁殖。我们提出的产品预计将是第一个商业上可行的口服铁替代疗法，可以安全地自我管理的病人。

DESCRIPTION (provided by applicant): Iron deficiency is frequently encountered in chronic kidney disease (CKD) patients and many other populations. Current oral iron formulations are poorly tolerated. Injectable iron preparations are difficult to administer, costly and have serious adverse reactions. Therefore, a highly absorbable, well tolerated oral iron supplement for the treatment of anemia associated with chronic kidney disease (CKD) is needed to complement erythropoiesis-stimulating agents. Our iron replacement agent will have the following attributes: 1) oral delivery with minimal adverse events, 2) efficient intestinal transit with vascular system entry, 3) liver targeting where the iron is released to normal iron stores and 4) cost-effective manufacture providing savings to the medical economy. Our Phase I SBIR application is designed to synthesize prototype products fitting this description. This will be accomplished by applying the company's nano-technology expertise to develop a stable iron oxide colloid having a surface coating to permit intestinal transport while protecting against bacterial bloom within th gut. Our proposed product is expected to be the first commercially feasible oral iron replacement therapy that can be safely self-administrated by the patient.